DSE : IBP

Indo-Bangla Pharmaceuticals Limited — Key statistics

Pharmaceutical Preparations · Bangladesh

Last price 13.1 BDT (At close: Oct 29, 2026) · Market cap 1.52B

Latest research: Indo-Bangla Pharmaceuticals financial analysis: qualified FY2025 audit; FY2025 revenue 21.3% of FY2020 (Oct 2026) · Indo-Bangla Pharmaceuticals: revenue of BDT 184.2m in FY2025 against BDT 866.1m in FY2020, a qualified audit with a going-concern paragraph, and 9M FY2026 profit of BDT 2.8m

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Technical report: trend, RSI, support and resistance, charts

Key statistics

Valuation

Measure	Value
Market Cap	1.52B
Enterprise Value	1.54B

Dates

Measure	Value
Earnings Date	Nov 4, 2026
Ex-Dividend Date	Dec 8, 2025

Measure	Value
Current Share Class	116.21M
Shares Outstanding	116.21M
Shares Change (YoY)	-2.37%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	22.38%
Owned by Institutions (%)	2.04%
Float	90.19M

Ratios

Measure	Value
PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.29
PB Ratio	1.04
P/TBV Ratio	1.04
P/FCF Ratio	26.79
P/OCF Ratio	26.53
PEG Ratio	n/a

Evratios

Measure	Value
EV / Earnings	n/a
EV / Sales	6.36
EV / EBITDA	63.80
EV / EBIT	n/a
EV / FCF	27.08

Financialposition

Measure	Value
Current Ratio	4.23
Quick Ratio	2.33
Debt / Equity	0.01
Debt / EBITDA	0.75
Debt / FCF	0.32
Interest Coverage	-7.03

Financialefficiency

Measure	Value
Return on Equity (ROE)	-0.95%
Return on Assets (ROA)	-0.14%
Return on Invested Capital (ROIC)	-0.26%
Return on Capital Employed (ROCE)	-0.24%
Weighted Average Cost of Capital (WACC)	5.26%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	127
Asset Turnover	0.14
Inventory Turnover	1.54

Taxes

Measure	Value
Income Tax	10.02M
Effective Tax Rate	n/a

Stockprice

Measure	Value
Beta (5Y)	0.19
52-Week Price Change	+16.96%
50-Day Moving Average	15.02
200-Day Moving Average	14.66
Relative Strength Index (RSI)	45.15
Average Volume (20 Days)	782,762

Shortselling

Measure	Value
Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Incomestatement

Measure	Value
Revenue	242.10M
Gross Profit	48.41M
Operating Income	-3.86M
Pretax Income	-4.37M
Net Income	-14.39M
EBITDA	24.12M
EBIT	-3.86M
Loss Per Share	-0.12

Balancesheet

Measure	Value
Cash & Cash Equivalents	1.58M
Total Debt	18.15M
Net Cash	-16.56M
Net Cash Per Share	-0.14
Equity (Book Value)	1.46B
Book Value Per Share	12.56
Working Capital	336.58M

Cashflow

Measure	Value
Operating Cash Flow	57.38M
Capital Expenditures	-560,000
Depreciation & Amortization	27.98M
Net Borrowing	-1.85M
Free Cash Flow	56.82M
FCF Per Share	0.49

Margins

Measure	Value
Gross Margin	19.99%
Operating Margin	-1.59%
Pretax Margin	-1.81%
Profit Margin	-5.94%
EBITDA Margin	9.96%
EBIT Margin	-1.59%
FCF Margin	23.47%

Dividends

Measure	Value
Dividend Per Share	0.02
Dividend Yield	0.11%
Dividend Growth (YoY)	50.00%
Years of Dividend Growth	1
Payout Ratio	n/a
FCF Payout Ratio	3.07%
Buyback Yield	2.37%
Shareholder Yield	2.48%
Earnings Yield	-0.95%
FCF Yield	3.73%

Analystforecasts

Measure	Value
Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Stocksplits

Measure	Value
Last Split Date	Jun 14, 2022
Split Type	Forward
Split Ratio	1.03

Scores

Measure	Value
Altman Z-Score	3.85
Piotroski F-Score	4

Fairvalue

Measure	Value
Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a